Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares Issued
Ratios

Zevra Therapeutics (ZVRA) Long-Term Debt Repayments (2016 - 2024)

Historic Long-Term Debt Repayments for Zevra Therapeutics (ZVRA) over the last 7 years, with Q2 2024 value amounting to $42.7 million.

  • Zevra Therapeutics' Long-Term Debt Repayments rose 2052801.93% to $42.7 million in Q2 2024 from the same period last year, while for Sep 2025 it was $42.7 million, marking a year-over-year decrease of 997.45%. This contributed to the annual value of $42.7 million for FY2024, which is 14356.85% up from last year.
  • Zevra Therapeutics' Long-Term Debt Repayments amounted to $42.7 million in Q2 2024, which was up 2052801.93% from $4.7 million recorded in Q4 2023.
  • Zevra Therapeutics' Long-Term Debt Repayments' 5-year high stood at $42.7 million during Q2 2024, with a 5-year trough of -$207000.0 in Q3 2023.
  • Its 3-year average for Long-Term Debt Repayments is $16.4 million, with a median of $8.8 million in 2023.
  • Over the last 5 years, Zevra Therapeutics' Long-Term Debt Repayments had its largest YoY gain of 2052801.93% in 2024, and its largest YoY loss of 2052801.93% in 2024.
  • Over the past 3 years, Zevra Therapeutics' Long-Term Debt Repayments (Quarter) stood at $37.9 million in 2021, then tumbled by 87.53% to $4.7 million in 2023, then surged by 802.56% to $42.7 million in 2024.
  • Its last three reported values are $42.7 million in Q2 2024, $4.7 million for Q4 2023, and -$207000.0 during Q3 2023.